Abstract:Human papillomavirus (HPV) is a primary oncogenic driver of cancers of the anal canal (AC), uterine cervix (UC), and oropharynx (OPX). Circulating tumor HPV DNA (ctHPVDNA) may assist in cancer detection, risk stratification, treatment assessment, and surveillance. The purpose of this study was to determine pre-treatment detectability of HPV ctDNA in OPX, AC, and UC cancer patients and to investigate the association of pretreatment ctHPVDNA quantity with clinical and pathologic factors and disease recurrence. Patients with newly diagnosed cancers of the AC, UC, and OPX referred for definitive chemoradiotherapy (CRT) participated in a prospectively collected IRB-approved serum biobank. Serum was collected prior to the initiation of CRT and was analyzed in a blinded fashion for HPV (serotypes 16, 18, 31, and 33) E6 and E7 ctDNA using a digital droplet PCR multiplex assay. Univariate associations between pre-treatment ctHPVDNA level and pre-treatment patient characteristics or disease recurrence were assessed using Fisher's exact test or Wilcoxon rank sum test and a univariate Fine and Gray Cox regression model, respectively. Seventy-one patients were included. Distribution of primary site was 18 OPX, 33 AC, and 20 UC. Forty-one (58%) of the 71 patients were confirmed to be p16+ or HPV+, 3% were HPV-negative, and 39% were unknown. ctHPVDNA was detectable in 89% of OPX, 85% anal canal, and 60% of cervical cancer patients. Of 41 patients with known p16+ or HPV+ status, 28 patients (68%) had detectable ctHPVDNA. Median copy number per mL was 41.7 in the total cohort, 1054.2 (range 17.5-161083.3) in OPX, 479.2 (range 22.9-38500.0) in AC, and 39.2 (range 12.9-39666.7) in UC patients. There was no association between ctHPVDNA detectability and age at diagnosis, sex, smoking history, T stage, N stage, or M stage. Among patients with cervical cancer, ctHPVDNA was detectable in 80% of patients with squamous or adenosquamous histology vs 25% of patients with adenocarcinoma (p = 0.0314). The median follow-up for all patients was 27 months (IQR 17.9-34.3 months). Recurrence at any site occurred in 14 of 71 patients (19.7%). Compared to patients with undetectable ctHPVDNA, detectable ctHPVDNA was not associated with disease recurrence (hazard ratio 0.925, 95% CI 0.266-3.217, p = 0.902). There was no association between ctHPVDNA copy number and recurrence when stratifying by <200 copies per mL versus >200 copies per mL. We demonstrate the feasibility of pre-treatment ctHPVDNA detectability in patients with squamous or adenosquamous carcinoma of the oropharynx, anal canal, and uterine cervix. This is the first validation of a ctHPVDNA assay in anal canal and cervical cancer. Further investigation of ctHPVDNA levels pre-treatment, post-treatment, and during surveillance in these malignancies is warranted.

Relating pre-treatment non-Gaussian intravoxel incoherent motion diffusion-weighted imaging to human papillomavirus status and response in oropharyngeal carcinoma

Differentiating Laryngeal Carcinomas from Precursor Lesions by Diffusion-Weighted Magnetic Resonance Imaging at 3.0 T: a Preliminary Study.

Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program

Predictive potential of dynamic contrast-enhanced MRI and plasma-derived angiogenic factors for response to concurrent chemoradiotherapy in human papillomavirus-negative oropharyngeal cancer

Diffusion-weighted MRI to detect early response to chemoradiation in cervical cancer: A systematic review and meta-analysis

Longitudinal Assessment of Intravoxel Incoherent Motion Diffusion Weighted Imaging in Evaluating the Radio-sensitivity of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy.

Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer

High resolution diffusion weighted imaging for neoadjuvant chemotherapy assessment of nasopharyngeal carcinoma

Circulating tumor HPV DNA in the management of HPV+ oropharyngeal cancer and its correlation with MRI

The value of intravoxel incoherent motion model-based diffusion-weighted imaging for predicting long-term outcomes in nasopharyngeal carcinoma

Use of Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) to Predict Early Response to Anti-Tumor Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): a Comparison of Intravoxel Incoherent Motion-Derived Parameters and Apparent Diffusion Coefficient

Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy

Intravoxel incoherent motion MRI for predicting early response to induction chemotherapy and chemoradiotherapy in patients with nasopharyngeal carcinoma

Application of Radiomics for the Prediction of HPV Status for Patients with Head and Neck Cancers.

MRI for Differentiation between HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma: A Systematic Review

The clinical utility of diffusion-weighted imaging in diagnosing and predicting treatment response of laryngeal and hypopharyngeal carcinoma: A systematic review and meta-analysis

HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: results from the DAHANCA 19 study

Multiparametric functional MRI and 18F-FDG-PET for survival prediction in patients with head and neck squamous cell carcinoma treated with (chemo)radiation

Pre-Treatment Circulating Tumor Human Papillomavirus (HPV) DNA and Recurrence Risk in HPV Associated Malignancy: Oropharyngeal, Anal Canal, and Cervical Cancer

The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments

Multiparametric MRI for evaluation of pathological response to the neoadjuvant chemo-immunotherapy in resectable non-small-cell lung cancer